Recce Pharmaceuticals Investor Relations Material

Recce Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development of synthetic anti-infectives to treat serious and hard-to-treat infections. The company’s proprietary technology focuses on creating broad-spectrum antibiotics designed to address antibiotic-resistant bacteria and viral infections. Recce’s primary products target bacterial sepsis, bloodstream infections, and other drug-resistant infections. Its approach to antimicrobial development aims to tackle the global challenge of antibiotic resistance through innovative, synthetic compounds that enhance treatment efficacy. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.